Rational design of GRK2 inhibitors for the treatment of heart failure
2017-01-16 03:42:51JohnTESMERHelenWALDSCHMIDTMarieCATOReneeBOULEYOsvaldoCRUZRODRIGUEZScottLARSEN
中國(guó)藥理學(xué)與毒理學(xué)雜志 2017年10期
John J TESMER,Helen V WALDSCHMIDT,Marie C CATO,Renee BOULEY,Osvaldo CRUZ-RODRIGUEZ,Scott D LARSEN
(University of Michigan,1.Life Sciences Institute,3.Valteich Medicinal Chemistry Core,Ann Arbor Michigan 48109 USA;2.Department of Biological Sciences,Purdue University,West Lafayette Indiana 47907 USA)
中國(guó)藥理學(xué)與毒理學(xué)雜志2017年10期
- 中國(guó)藥理學(xué)與毒理學(xué)雜志的其它文章
- Identification and optimization of a potent and highly selective D3 dopamine receptor agonist
- Protective role of FoxO transcription factors against oxidative stress-induced chondrocyte dysfunction:a new therapeutic target for osteoarthritis
- Meta-analysis of serum copper and heart failure
- Involvement of cysteinyl leukotriene signaling in microglial morphological changes and CASP1 expression in vitro
- Inhibitory effect of compound NS5806 on cardiac transient outward potassium channel dependents on interaction between auxiliary subunits
- Connexin 40-formed GJIC increases the phototoxicity of photodynamic therapy through ROS-and calcium-mediated pathways